Medical Cannabis for ADHD, Autism, Tourette's, OCD, PTSD, Anxiety, Depression, Insomnia, Eating, and Personality Disorders: A Review

Dr Alan Cross – Clinical Deep Dive

Medical Cannabis for ADHD, Autism, Tourette's, OCD, PTSD, Anxiety, Depression, Insomnia, Eating, and Personality Disorders: A Review

Abstract

Medical cannabis has emerged as a potential therapeutic in various psychiatric and neurodevelopmental disorders amid growing patient use and legislative changes. This review synthesizes current evidence on cannabinoid-based interventions for attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder (ASD), Tourette's syndrome, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), anxiety disorders, major depressive disorder (MDD), insomnia, eating disorders (notably anorexia nervosa), and personality disorders. For each condition, we examine preclinical mechanisms, clinical efficacy, safety, and study limitations.

Findings: Cannabinoids such as Δ^9-tetrahydrocannabinol (THC) and cannabidiol (CBD) show promise in alleviating certain symptom domains (e.g. tics in Tourette's, anxiety and sleep disturbances in PTSD and insomnia, aggressive behaviours in ASD) but clinical data remain limited and mixed. For many disorders (ADHD, MDD, OCD, personality disorders), evidence of therapeutic benefit is inconclusive or absent, whereas modest benefits are more evident in others (notably PTSD, anxiety, insomnia, Tourette's, and some ASD-associated symptoms).

Proposed mechanisms include modulation of neurotransmitter systems (endocannabinoid regulation of dopamine, GABA, glutamate, and serotonin) and facilitation of fear extinction and neuroplasticity.

Safety profile: CBD is generally well tolerated with minimal adverse effects, while THC-dominant therapies carry risks of sedation, cognitive impairment, and dependence. Side effects such as slowed cognition, memory lapses, and anxiety can occur with THC, and paediatric use raises additional concerns about neurodevelopment.

Limitations: Most studies are small, short-term, or observational, and lack standardized formulations and dosing. RCT's with whole plants use are unlikely to happen due to the complex nature of each and every variant of cannabis plant.

Conclusion: Current evidence does not yet generally support broad clinical use of medical cannabis in these conditions, but targeted benefits in select scenarios warrant further rigorous trials and is already implemented in several key conditions, off label. Clinicians should weigh potential therapeutic gains against risks, and regulatory frameworks must facilitate research while ensuring safe, ethical use.

Introduction

Cannabis sativa and its derivatives have been used medicinally for centuries, and modern interest in medical cannabis has surged as many jurisdictions legalize its use. The plant contains Phytocannabinoids like THC (a psychoactive agonist at cannabinoid CB_1 receptors) and CBD (a non-intoxicating modulator of cannabinoid and non-cannabinoid receptors). These compounds engage the endogenous cannabinoid system, which regulates neurotransmitter release, stress responses, and neuroinflammation. Such mechanisms suggest plausible therapeutic effects across a spectrum of psychiatric and neurodevelopmental disorders. Indeed, preclinical models indicate cannabinoids can exert anxiolytic, antidepressant, antipsychotic, and sleep-modulating effects via interactions with serotonin 5-HT_1A receptors, GABAergic signalling, and fear memory extinction pathways.

Rationale: Conventional treatments for many mental health conditions (e.g. stimulants for ADHD, antipsychotics for Tourette's, SSRIs for anxiety/OCD, etc.) are not universally effective and often carry significant side effects. This has spurred interest in cannabinoids as alternative or adjunct therapies. Patients themselves report using cannabis to self-medicate symptoms of pain, anxiety, mood disorders, insomnia, and more. For example, epidemiologic data show anxiety (50%) and depression/mood (34%) are among the most common reasons cited for medical cannabis use.

Scope of Review: We present an academic review of evidence regarding medical cannabis (including whole-plant preparations and isolated THC/CBD formulations) in the management of ADHD, ASD, Tourette's syndrome, OCD, PTSD, anxiety disorders, MDD, insomnia, eating disorders, and personality disorders. For each condition, we summarize current clinical and preclinical research, putative mechanisms of cannabinoid action, therapeutic efficacy signals (or lack thereof), safety and side effect profiles, and limitations of existing studies. We also consider regulatory and ethical issues, particularly in vulnerable populations (such as children and adolescents or those prone to substance misuse). By collating findings from systematic reviews, randomized controlled trials (RCTs), meta-analyses, and other peer-reviewed studies, this review aims to provide an objective, evidence-based assessment of the therapeutic potential of cannabinoids in these diverse conditions.

Note: "Medical cannabis" in this context can refer to pharmaceutical-grade cannabinoids (e.g. purified CBD or THC, synthetic analogues like nabilone) as well as cannabis-based medicinal products (e.g. standardized extracts or nabiximols (THC:CBD oromucosal spray)). The term "CBMPs" (cannabis-based medicinal products) will be used when referring generally to regulated medical cannabis formulations.

Medical Cannabis in ADHD

Background: ADHD is a common neurodevelopmental disorder characterized by developmentally inappropriate levels of inattention, hyperactivity, and impulsivity. Standard treatments (stimulants like methylphenidate/amphetamine or non-stimulants like atomoxetine) are effective for many, yet some patients experience suboptimal response or intolerable side effects, leading a subset to experiment with cannabis for symptom relief. Epidemiological data indicate individuals with ADHD have higher rates of cannabis use than the general population, potentially reflecting attempts at self-medication. However, ADHD is also associated with increased risk of substance use disorder (SUD), making the impact of cannabis on this population a complex issue.

Mechanisms: The rationale for cannabinoid use in ADHD is largely theoretical. ADHD's pathophysiology involves dysregulated dopamine and norepinephrine in frontostriatal circuits; cannabinoids (particularly THC) acutely increase dopamine release in mesolimbic pathways, which might transiently improve attention or mood, though evidence of long-term benefit is lacking. Additionally, the endocannabinoid system plays a role in executive function and impulse control, suggesting potential targets. Small neuroimaging studies have yielded mixed findings: some report altered brain perfusion and cortical thickness in individuals with ADHD who use cannabis. Notably, one study found young adults with ADHD and early cannabis use had differences in thalamocortical connectivity, although causal relationships remain unclear. There is also interest in entourage effects of minor cannabinoids and terpenes on cognitive function, but this remains speculative.

Clinical Evidence: To date, rigorous clinical trials are sparse. Only one pilot RCT (30 adult patients) has specifically evaluated a cannabinoid-based medication in ADHD. In that trial, adults received an oromucosal spray containing THC:CBD (1:1, as in nabiximols) or placebo over six weeks. The results showed no statistically significant improvement in ADHD symptom ratings with the cannabinoid treatment compared to placebo. Some secondary outcomes suggested a trend toward reduced hyperactivity/impulsivity and improved inhibitory control, but these did not meet corrected significance thresholds. A recent systematic review (2023) similarly concluded that evidence is inconclusive: some observational or case reports claim ADHD symptom relief with cannabis, but most controlled data show no clear benefit. In fact, several studies indicate cannabis use in ADHD may correlate with worsened attention and executive function, especially in youth. Self-reports are mixed – while a subset of patients insist cannabis calms their racing thoughts or improves focus, others experience exacerbation of concentration difficulties. Thus, the current state of clinical evidence does not support recommending cannabis for ADHD symptom control, and existing positive anecdotes may reflect individual variability or placebo effects.

Safety and Risks: ADHD often co-occurs with disruptive mood and anxiety symptoms, and individuals may be particularly vulnerable to substance misuse. Cannabis use in this population raises concerns: cognitive side effects of THC (short-term memory impairment, reduced attention) could further hinder academic or occupational functioning. Indeed, acute THC has been shown to impair attention and decision-making –

an important consideration for patients prone to impulsivity. Adolescents with ADHD who use cannabis regularly show, on average, lower educational attainment and more severe executive dysfunction than non-using peers. Moreover, ADHD patients are nearly eight times more likely to develop cannabis use disorder if using regularly, possibly due to overlapping dopamine-related vulnerabilities. On the other hand, CBD-predominant products, which lack THC's intoxicating effects, may pose fewer cognitive risks; however, there is virtually no clinical data on isolated CBD for ADHD. Side effects reported in the single RCT of THC/CBD spray were mild, with no serious adverse events. Common THC-related effects such as sedation or light-headedness can occur**,** and any potential benefits must be weighed against these. For paediatric ADHD, the ethical barrier is high – given the unknown long-term effects of cannabis on the developing brain, experts urge extreme caution (or avoidance) in youth.

Limitations and Future Directions: The evidence base is limited and of low quality, consisting mostly of observational studies with high risk of bias. No large-scale RCTs have been completed. Key knowledge gaps include: optimal cannabinoid composition (THC vs CBD or combined), dosing strategies, and identification of any ADHD subgroups that might benefit (for instance, adults with predominantly hyperactive vs inattentive symptoms). Future trials should examine whether cannabinoids could serve as adjuncts to standard stimulant medication (e.g. to manage comorbid anxiety or sleep issues in ADHD) or if they have any role as monotherapy. Given preliminary neuroimaging hints, research into how cannabinoids modulate dopamine transporter density or neural oscillations in ADHD could elucidate mechanisms. Importantly, long-term follow-up is needed to ensure that use of medical cannabis does not adversely affect developmental trajectories in younger patients. For now, clinicians are advised that current evidence is insufficient to endorse cannabis for ADHD, and patients should be informed about the potential for ineffectiveness and harms.

Autism Spectrum Disorder (ASD)

Background: Autism spectrum disorder is a neurodevelopmental condition characterized by challenges in social communication and the presence of repetitive behaviours or restricted interests. Many individuals with ASD also experience comorbid symptoms such as intellectual disability, epilepsy, severe irritability/aggression, anxiety, and sleep disturbances. Conventional pharmacotherapies (e.g. antipsychotics like risperidone for irritability) can mitigate some behavioural issues but often provide incomplete relief and cause notable side effects (weight gain, sedation, metabolic issues). Parents and caregivers have increasingly explored CBD-rich cannabis extracts as alternative treatments for difficult-to-manage ASD behaviours. Early interest was spurred by anecdotal successes and the recognition that the endocannabinoid system might be implicated in ASD pathophysiology (e.g. some studies show altered endocannabinoid levels in autistic individuals).

Proposed Mechanisms: Cannabinoids might influence ASD symptoms via multiple pathways. CBD has anxiolytic and anti-aggressive properties, possibly through serotonin receptor agonism and reduction of glutamate release, which could attenuate sensory hypersensitivity and anxiety-driven behaviours common in autism. There is also evidence from animal models that modulating the CB_2 receptors (expressed in immune cells and glia) might affect neuroinflammation associated with autism. Neuroimaging trials in ASD patients have shown that a single dose of CBD can alter brain excitation-inhibition balance: for example, magnetic resonance spectroscopy indicated CBD increased cortical GABA+ levels and altered glutamate concentrations in key brain regions. These shifts might correlate with improved neuronal signalling in ASD. THC's role is less clear – while low doses could theoretically reduce hyperactivity via CB_1-mediated dampening of neuronal excitability, THC also carries a risk of behavioural disinhibition or anxiety in some individuals. Notably, many medical cannabis preparations used for ASD are CBD-rich with only trace THC (e.g. 20:1 CBD:THC ratio) to minimize psychoactive effects while leveraging CBD's potential benefits. The combined actions of cannabinoids on ion channels, neurotransmitters, and possibly oxytocin release form the basis of ongoing hypotheses for autism treatment.

Clinical Evidence: Research on cannabinoids in ASD has accelerated in recent years. Several observational studies and a few randomized trials have been conducted, primarily focusing on CBD-enriched formulations. Results have been cautiously encouraging for associated symptoms: in open-label series, caregivers reported improvements in irritability, aggressive outbursts, self-injurious behaviour, hyperactivity, and sleep problems in about half to two-thirds of children treated with CBD-rich cannabis oils. For instance, a large retrospective Israeli study (2019) of 188 children using a 30% CBD oil found behavioural improvements in 80% of patients, including reduced rage attacks and better communication, along with notable reductions in anxiety and sleep difficulties. Another case series observed significant improvement on the Caregiver Global Impression scale in quality of life, mood, and adaptive behaviours for most participants after 6–9 months of CBD treatment.

More robust data are emerging from controlled trials. A randomized placebo-controlled trial in 2018 (n≈60) using a 20:1 CBD:THC oil reported decreased disruptive behaviours in the treatment group, although effects on core ASD symptoms were minimal. A 2021 systematic review concluded that cannabinoids (mainly CBD formulations) show "promising effects on some ASD-associated problems (e.g. aberrant behaviours, hyperactivity, sleep disturbances, seizures)", but little evidence of improvement in core social communication deficits or repetitive behaviours. In other words, medical cannabis may help manage co-occurring symptoms that significantly impair daily functioning, even if it does not alter autism's fundamental social and cognitive features. This review noted the heterogeneity of study designs and outcomes, which precluded meta-analysis. Only a few RCTs have been published to date, and while some showed positive trends (e.g. reductions in severe behaviour problems on parent-rated scales), others did not reach statistical significance on primary endpoints due to small sample sizes. Ongoing trials (including multi-centre studies of CBDV – cannabidivarin, a CBD analogue – and various CBD/THC ratios) are expected to provide clearer answers.

Safety and Tolerability: Encouragingly, available data suggest cannabinoid treatments are generally well tolerated in ASD, with mostly mild side effects. Reported adverse effects include somnolence, increased appetite, diarrhoea, and occasional irritability or agitation. Notably, these were often transient or resolved with dose adjustments. In a compassionate use study of 18 youths, some experienced increased irritability on one cannabis strain, which was resolved by switching to a different cannabinoid profile. Importantly, no severe or long-term adverse events (like seizures or psychosis) were definitively linked to treatment in the published studies. THC at the low doses used (often <0.5 mg/kg) has not been reported to cause intoxication in these children, though subtle cognitive or developmental effects cannot be ruled out without longer follow-up. One theoretical concern is whether chronic cannabinoid use during childhood could impact brain maturation or endocannabinoid system development; thus far, the limited durations studied (mostly <1 year) and the focus on CBD (which is non-euphoric) are somewhat reassuring. Still, careful monitoring of cognitive and pubertal development is warranted in any long-term paediatric use.

Limitations: The current evidence base, while growing, has significant limitations. Many studies are open-label or lack appropriate control groups, raising placebo effect concerns. Small sample sizes and variability in formulations (different CBD:THC ratios, purity, etc.) make it hard to generalize findings. Outcomes measured also vary; some focus on parent-rated global improvements, others on specific symptom scales, complicating comparisons. Additionally, core autism symptoms (social interaction and communication deficits) have not shown clear improvement – highlighting that cannabis is not a curative treatment for ASD, but rather a symptomatic management tool. Heterogeneity of the autism spectrum means a subset of patients might respond while others do not, and predictors of response are unknown. Blinding is a challenge in these trials because psychoactive effects (even mild sedation) may reveal who is on active treatment, potentially biasing caregiver reports.

Future Research: High-quality RCTs with standardized cannabinoid formulations are needed to determine efficacy and optimal dosing more definitively. Studies should stratify

results by subgroups (e.g. ASD with versus without intellectual disability or epilepsy) to see who benefits most. Investigating mechanistic biomarkers – for example, measuring changes in neurotransmitter levels or network connectivity pre- and post-cannabinoid treatment (as done in the Pretzsch et al. imaging studies) – could clarify how cannabinoids might alleviate certain autistic symptoms. Long-term studies are also critical to assess sustained benefits and any impacts on development or adaptive functioning. On the regulatory side, some countries (like Israel and parts of the US) now allow medical cannabis use for severe autism under compassionate programs, reflecting public demand. This underscores an ethical imperative to gather rigorous data so that clinicians can guide families with evidence rather than anecdote. In summary, cannabinoid therapy in ASD appears promising for managing specific problem behaviours and comorbidities, but it remains an experimental approach pending further validation.

Tourette's Syndrome

Background: Tourette's syndrome (TS) is a neurodevelopmental tic disorder characterized by motor and vocal tics that fluctuate in severity. Comorbid conditions like ADHD, OCD, and anxiety are common in Tourette's. Standard treatments (antidopaminergic drugs such as haloperidol or aripiprazole, and alpha-2 agonists like clonidine) can reduce tics but often provide only partial relief and can cause sedation, cognitive dulling, or extrapyramidal side effects. Notably, cannabis has a historical and patient-reported track record for improving tics. Several TS patients have self-reported that smoking cannabis markedly reduces tic frequency and intensity, observations which prompted formal clinical investigation in the early 2000s. The endocannabinoid system is densely present in motor control regions (basal ganglia, cortex), providing a biological basis for potential effects on tics.

Mechanisms: The pathophysiology of tics involves dysregulated dopamine signalling in cortico-striato-thalamo-cortical loops. CB_1 cannabinoid receptors are abundant in the striatum and globus pallidus; stimulating these receptors (as THC does) can modulate release of neurotransmitters including dopamine and GABA, potentially suppressing excessive neural firing that produces tics. Additionally, cannabinoids might alleviate TS-related premonitory urges, anxiety, and OCD symptoms via their anxiolytic and habit-breaking properties. It's hypothesized that THC's central effect of dampening neuronal excitability underlies tic reduction. CBD's role is less direct, but it may synergize by mitigating THC's psychoactive side effects and possibly contributing to anxiolysis. Animal models of hyperdopaminergic stereotypies support that CB_1 agonists reduce such movements. Thus, THC-containing cannabis, carefully dosed, has been proposed as a therapy in severe Tourette's syndrome.

Clinical Evidence: Initial evidence for cannabis in TS came from small crossover trials. In two early studies (Müller-Vahl et al., 2002 and 2003), single doses of oral THC (dronabinol) were tested against placebo: results demonstrated significant tic reduction acutely and in a 6-week trial, with some patients also noting improved premonitory urge and obsessive-compulsive symptoms. Building on this, recent larger studies have reinforced the potential benefit. A 2023 placebo-controlled crossover RCT (22 patients with severe Tourette's) investigated an oral cannabis oil (containing equal THC and CBD at 5 mg/mL each). After 6 weeks of treatment, the active group saw a mean tic severity reduction nearly 9 points on the Yale Global Tic Severity Scale, compared to ~2.5 points with placebo. This difference was statistically and clinically significant, indicating a substantial decrease in tics. In this trial, 87% of participants on cannabis achieved a moderate-to-marked tic improvement, and some also had reductions in comorbid anxiety and OCD symptoms. Importantly, this RCT provides the strongest evidence to date that cannabinoids can ameliorate tics in severe Tourette's. A systematic review and meta-analysis of all clinical trials up to 2021 similarly concluded that cannabis-based medicines are associated with tic reduction and improvements in quality of life, although it noted that sample sizes were small and methodologies varied.

Real-world and observational data support these findings: in countries where medical cannabis is allowed for TS (e.g. Germany and Canada), patient registries have documented notable tic improvements in a majority of cases using THC-containing preparations. Some patients who failed conventional therapy have become tic-free or nearly so on nightly cannabis use (though these dramatic responses are anecdotal). Overall, the evidence, while limited, points to cannabinoids – particularly THC – as effective in reducing tic severity for many patients with refractory Tourette's.

Side Effects and Considerations: The side-effect profile in Tourette's trials mirrors known effects of THC. In the 2023 RCT, some patients on active drug experienced slowed mentation, short-term memory lapses, and poor concentration. These cognitive side effects were generally mild but notable, given that TS patients often need to function academically or at work. Sedation and dry mouth have also been reported. In comparison to antipsychotic medications, cannabinoids were relatively well tolerated: no extrapyramidal symptoms or weight gain occur with cannabis. Still, one must be cautious that adolescents with TS (who often have an onset in childhood) could be vulnerable to THC's effects on the developing brain; thus most trials have focused on adults. Dependency risk exists – though TS patients typically use lower, controlled doses, any long-term THC regimen can lead to tolerance or withdrawal. Encouragingly, no patients in recent studies discontinued due to side effects, and none had serious adverse events attributable to cannabis.

One intriguing observation is that some TS patients require only very low doses of THC (e.g. 2–5 mg) for tic control – far lower than recreational use – suggesting a narrow therapeutic window that minimizes cognitive impairment. The addition of CBD may further mitigate anxiety or potential psychotomimetic effects of THC. In the context of Tourette's, where comorbid OCD or anxiety can amplify tic severity, the anxiolytic effect of cannabis might confer a dual benefit. Indeed, the NEJM Evidence study noted possible reduction in tic-related anxiety and OCD symptoms with cannabinoids.

Limitations: While the therapeutic signal is clear, data are still from relatively small samples. Questions remain about optimal formulation: is a THC isolate (dronabinol) as effective as a combined THC/CBD product? Does inhaled cannabis (which some patients use) provide more rapid tic relief than oral oil? Long-term efficacy is also unknown – do benefits sustain over years, and does tolerance to tic-suppressing effects develop? Some case series suggest continued benefit for several years without dose escalation, but controlled long-term studies are needed. Additionally, not all patients respond; identifying predictors (perhaps pharmacogenetic markers or tic subtypes) could help target therapy. From a regulatory standpoint, Tourette's is increasingly recognized in medical cannabis programs (several US states and European countries include it), but insurance coverage and physician comfort in prescribing remain hurdles.

Future Directions: Larger multi-centre trials are warranted to confirm efficacy and determine dosing guidelines. Research into cannabinoid mechanisms in TS could explore whether endocannabinoid levels differ in ticking vs non-ticking states, or if cannabinoids influence brain regions like the supplementary motor area known to be involved in tics. There is also interest in alternate cannabinoids – e.g. THCV (tetrahydrocannabivarin),

which has mild CB_1 antagonist and CB_2 agonist properties, and how they might affect tics or impulsivity. Finally, comparative effectiveness studies between cannabis and existing tic medications would help clarify its place in therapy. In summary, for severe, treatment-refractory Tourette's syndrome, medical cannabis (with THC) has shown potentially effective outcomes in reducing tics, representing a promising avenue when standard treatments fail. Clinicians should remain mindful of side effects, but cannabinoids are emerging as a legitimate component of the TS treatment armamentarium pending further evidence.

Obsessive-Compulsive Disorder (OCD)

Background: OCD is a chronic psychiatric disorder characterized by intrusive, anxiety-provoking thoughts (obsessions) and repetitive behaviours or mental acts (compulsions) performed to reduce distress. First-line treatments—SSRIs and cognitive-behavioural therapy with exposure and response prevention (ERP)—are effective for many but not all patients. A significant subset remains treatment-resistant, leading to exploration of novel interventions. The endocannabinoid system is implicated in anxiety and fear extinction, processes relevant to OCD. Patients with OCD also have high rates of anxiety and sometimes Tourette's tics, hinting that treatments effective in those domains (like cannabinoids) might benefit OCD symptoms. Some individuals with OCD have self-reported that smoking cannabis provides short-term relief from obsessive thoughts and urgency to ritualize, which has driven scientific inquiry into cannabinoids as a possible therapeutic tool.

Mechanistic Rationale: OCD involves hyperactivity in cortico-striatal-thalamo-cortical circuits and an imbalance in glutamate/GABA in the cortico-striatal pathways. CB_1 receptors in these circuits can modulate neurotransmitter release. It is hypothesized that cannabinoids (particularly THC) might reduce the intensity of obsessive thoughts and compulsive urges by dampening neural excitability in these loops, thereby interrupting the "loop" of obsession → anxiety → compulsion. Additionally, the anxiolytic and stress-dampening effects of cannabinoids could lower the general anxiety that fuels OCD symptoms. CBD may aid in fear extinction and memory consolidation, potentially enhancing the effects of exposure therapy by helping patients "unlearn" obsessive fears. Preclinical support comes from animal models: for example, CBD reduced marble-burying behaviour (a rodent compulsive analogue) in some studies, and FAAH inhibitors (which increase levels of the endocannabinoid anandamide) have shown anti-compulsive effects in mice. These findings suggest boosting endocannabinoid signalling could relieve OCD-like behaviours, at least transiently.

Clinical Evidence: High-quality clinical trial data in OCD are scant. However, a few lines of evidence exist:

- Acute Symptom Relief: A 2020 study analysed data from a symptom-tracking app (Strainprint) where 87 individuals with OCD recorded their symptom severity before and after cannabis use. The results were striking: on average, patients reported a 60% reduction in compulsions, 49% reduction in intrusive thoughts, and 52% reduction in anxiety immediately after inhaling cannabis. Higher CBD content and higher doses were associated with larger reductions in compulsive behaviours. Notably, over time there was some evidence of tolerance to the effect on obsessions (intrusive thoughts), as later sessions showed slightly less improvement than initial ones. While this was an uncontrolled observational study, it provides real-world evidence that inhaled cannabis can acutely alleviate OCD symptoms in the short term. Patients often report that the anxiety and urgency of obsessions diminish after cannabis use, making it easier to resist compulsions for a time.

- Laboratory Challenge Study: Another trial (2020, Kayser et al.) used a human laboratory model where OCD patients were given either oral THC (dronabinol) or placebo and then exposed to a personalized symptom provocation. The cannabinoid condition was associated with lower compulsive urges during the provoked anxiety scenario compared to placebo in some participants. Though modest and not unanimous, these findings hint that THC may acutely blunt the distress or urge tied to obsessions, facilitating better tolerance of anxiety.
- Augmentation of Therapy: A small pilot from Mexico (2021) combined THC analogue (nabilone) with therapy in OCD patients and suggested a synergistic benefit, with greater reductions in Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) scores when exposure therapy was paired with cannabinoid use versus therapy alone. This aligns with the idea that cannabinoids might enhance the extinction learning during ERP by calming the patient and perhaps affecting memory reconsolidation of fear responses.

Overall, these early studies indicate a potential therapeutic effect of cannabinoids on OCD symptoms, at least in the short term. Patients often describe feeling less anxious and more able to dismiss obsessive thoughts after cannabis. However, no large RCTs have yet tested a cannabinoid as a dedicated treatment for OCD in a longitudinal fashion.

Safety and Caveats: Using cannabis for OCD is not without concerns. OCD patients can be sensitive to substance effects, and while many tolerate cannabinoids well, some might experience paradoxical anxiety or panic (especially with high-THC strains). It's noteworthy that in the app-based study, the symptom relief came with few side effects reported in session logs – likely because patients self-titrated to a comfortable dose. Nonetheless, THC can cause acute cognitive impairment (attention, memory) which might interfere with daily functioning if someone medicates frequently. The development of tolerance observed for intrusive thoughts suggests that increasing doses might be needed over time, raising the risk of dependence. Indeed, one limitation of relying on cannabis is the possibility of a rebound effect: when its effects wear off, anxiety and obsessions might spike, potentially reinforcing a cycle of frequent use.

There is also the complexity that OCD often overlaps with depression; heavy cannabis use might worsen motivation and mood in the long run for such individuals. Some case reports even note cannabis-induced OCD symptoms in rare instances (though generally high doses), illustrating a paradox that likely depends on individual neurobiology. Importantly, no serious adverse events have been reported in the small OCD-related studies. CBD, being non-intoxicating, could be a safer long-term candidate; while formal studies on CBD alone for OCD are lacking, its anti-anxiety effect has been documented in other contexts.

Limitations: Current evidence for cannabis in OCD is preliminary and mostly short-term. The lack of controlled trials means we don't know if cannabinoids truly outperform placebo when expectation biases are removed. The app study had a self-selected sample and relied on self-report (with no placebo control). Therefore, while the magnitude of reported symptom reduction is impressive, it must be interpreted cautiously. Additionally, the long-term impact of using cannabis to "escape" obsessive anxiety could interfere with the principles of ERP therapy, which require tolerating anxiety to learn that fear subsides

without compulsion. There's a theoretical risk that cannabis, if used as a crutch, could impede development of coping skills or even become a new compulsion (using the drug whenever anxiety arises). These are considerations future research must address.

Future Research: A logical next step is an RCT of CBD or THC (or a combination) vs placebo in OCD, measuring changes in Y-BOCS over several weeks. Such a trial could also evaluate whether cannabinoids are best used as adjuncts to ERP therapy (to make exposures more tolerable) or as stand-alone anxiolytics for patients who cannot engage in therapy. Neuroimaging could help clarify if cannabinoids reduce activity in the orbitofrontal cortex or caudate (regions hyperactive in OCD). Given the early hint that CBD may enhance fear extinction (seen in PTSD studies and healthy volunteers), investigating CBD prior to therapy sessions could be fruitful. On the other hand, microdoses of THC might be studied in acute challenge paradigms to optimize the anxiolytic vs anxiogenic balance. In summary, cannabinoids show a potential short-term benefit in alleviating OCD symptoms (especially anxiety and compulsive urge reduction), but careful research is needed to establish efficacy, safety in long-term use, and how to integrate such treatment without undermining standard therapy.

Post-Traumatic Stress Disorder (PTSD)

Background: PTSD is a trauma and stress-related disorder arising after exposure to life-threatening or violent events. Core symptoms include intrusive memories (flashbacks, nightmares), avoidance of trauma reminders, negative mood/cognitions, and hyperarousal (insomnia, irritability, exaggerated startle). Many patients, particularly combat veterans and survivors of violence, have turned to cannabis to manage PTSD symptoms – so much so that PTSD is now an approved indication for medical cannabis in many U.S. states. Traditional treatments (SSRIs, prazosin for nightmares, trauma-focused psychotherapies) have limited success for some, leading to interest in cannabinoids. The endocannabinoid system is deeply involved in memory, fear extinction, and emotional regulation, making it a promising target for PTSD. In fact, PTSD patients have been found to have dysregulated endocannabinoid levels, such as lower anandamide (an endogenous cannabinoid) which could contribute to impaired fear extinction. This biological insight, combined with ample anecdotal evidence of symptom relief, has driven research into both THC-containing cannabis and CBD for PTSD.

Proposed Mechanisms: Cannabinoids may address PTSD symptoms on multiple fronts. Memory processing: Activation of CB_1 receptors by THC can facilitate extinction learning – i.e. the process of decoupling triggers from traumatic fear responses. Preclinical studies show that cannabinoids accelerate the extinction of conditioned fear and reduce learned fear responses, which is exactly what therapies for PTSD aim to do. This suggests cannabis might reduce the intensity and frequency of traumatic memories or their emotional impact. Nightmares: The REM-suppressing effect of THC is thought to disrupt nightmare formation. Synthetic THC analogues (like nabilone) have been shown to substantially reduce or eliminate nightmares in PTSD. Hyperarousal: Both THC and CBD have sedative/calming effects that could alleviate hypervigilance, insomnia, and startle reactivity. Mood and anxiety: CBD's anxiolytic properties might improve generalized anxiety and depressive symptoms often co-occurring with PTSD, through 5-HT1A receptor agonism and cortisol modulation. Additionally, the endocannabinoid system modulates the hypothalamic-pituitary-adrenal (HPA) axis; enhancing endocannabinoid tone could normalize stress hormone levels, potentially helping the body "reset" from chronic fight-or-flight mode. Overall, the rationale is that cannabinoids might help 're-balance' a dysregulated neurobiological state after trauma, providing symptomatic relief and possibly enhancing therapeutic recovery.

Clinical Evidence: Research on cannabinoids for PTSD has grown from observational studies to a few controlled trials:

- Symptom reduction and observational data: Numerous surveys and retrospective studies have found that PTSD patients using cannabis report less severe symptoms than those who do not. For example, an observational study of veterans noted improved sleep quality and fewer nightmares with cannabis use. A 2021 systematic review of PTSD and cannabis identified 10 observational studies ($n \approx 4{,}700$ combined) that generally showed cannabis use was associated with reductions in overall PTSD symptom severity and improved quality of life in patients. Importantly, these were mostly non-randomized, high risk of bias studies,

but the consistency of patient-reported benefit (especially on intrusive memories and sleep) is notable. Adverse effects like dry mouth, headache, and acute euphoria/anxiety were reported by some, but overall cannabis was well tolerated in these populations. A small proportion did experience worsening of PTSD symptoms – this might relate to overuse or paradoxical reactions in certain individuals.

- Nightmare-focused RCTs: One of the landmark trials was a randomized crossover trial of nabilone (a synthetic THC analogue) for treatment-resistant nightmares in PTSD. In 10 patients, nabilone significantly reduced nightmare frequency and intensity compared to placebo. 72% of participants had either cessation or significant reduction of nightmares. Global clinical improvement was also better on nabilone (many were "much improved" vs only "minimally improved" on placebo). Importantly, this improvement occurred without any severe adverse events, and with some improvements in general well-being. Similarly, an open-label Canadian study of PTSD patients in a prison setting found that adding nabilone led to self-reported improvements in sleep duration and quality, as well as decreased daytime flashbacks and better pain control.
- Smoked cannabis RCT: The first placebo-controlled trial of smoked cannabis in PTSD (conducted with veterans, published 2021) tested strains of varying THC/CBD content. It found that all active cannabis varieties produced greater reductions in PTSD symptom severity than placebo over 3 weeks, although differences were modest and not statistically significant across all measures, likely due to small sample size. Still, it provided proof-of-concept that a THC-dominant strain and a THC+CBD strain both outperformed placebo in symptom improvement (around a 10-20% greater improvement) without serious side effects. This study also highlighted the challenge of maintaining blinding because many patients could discern placebo vs active due to psychoactive effects.
- CBD trials: There is interest in CBD as a monotherapy for PTSD to avoid THC's risks. A recent open-label trial gave 33 patients CBD (25–100 mg daily) for 8 weeks; 91% had decreased PTSD symptom scores, especially improvements in anxiety and sleep quality, and most tolerated it well. However, without a control group, placebo effects can't be ruled out. An ongoing RCT is examining CBD augmentation of prolonged exposure therapy, based on the hypothesis that CBD will enhance fear extinction learning during therapy sessions.

Taken together, the clinical evidence suggests cannabinoids – particularly those containing THC – can alleviate certain PTSD symptoms, especially nightmares and insomnia, and possibly overall symptom severity. Patients often describe that cannabis helps them fall asleep and stay asleep, reduces the frequency of nightmares, and makes flashbacks less intense or easier to cope with. Some also report improvement in mood and reduction in hyperarousal (feeling less on-edge).

Safety and Risks: PTSD populations include many who have struggled with substance use (alcohol, opioids, etc.), raising concerns about introducing cannabis. The studies so far indicate that cannabinoids are generally well tolerated in PTSD – no severe adverse effects or exacerbation of psychosis have been reported. Side effects are those expected from cannabinoids: transient dizziness, dry mouth, mild euphoria, or sedation in some cases.

Notably, a small subset experienced a worsening of PTSD symptoms (e.g. increased anxiety or re-experiencing). This could be due to overactivation of traumatic memories in an intoxicated state or heightened anxiety from too high a THC dose. Careful titration and patient education are crucial. There is also the risk of dependency: a randomized trial in 2022 (looking at immediate vs delayed cannabis access for PTSD) found that individuals given immediate access had a higher incidence of developing cannabis use disorder (CUD) within 12 weeks. This underscores that while cannabinoids can be therapeutic, monitoring and limiting misuse is critical, as some may become psychologically reliant on cannabis to cope, potentially hindering other therapeutic progress. Another consideration is cognitive: heavy cannabis use might impair memory and learning, which could interfere with trauma-focused psychotherapy effectiveness.

Regulatory/Ethical Considerations: Many jurisdictions now allow medical cannabis for PTSD, acknowledging patient demand. However, veterans affairs systems (like the U.S. VA) still caution that evidence is limited and have not universally endorsed it. Ethically, for severe PTSD that is life-threatening (due to suicide risk) and unresponsive to standard care, clinicians face a compassionate use dilemma – the relatively benign side effect profile of cannabinoids may be acceptable given the severity of suffering, even if evidence is not yet Level 1. But ensuring patients are informed about the uncertainty and potential risks of addiction is important.

Limitations: The biggest limitation is the lack of large-scale, long-term RCTs. Most evidence comes from observational studies susceptible to bias (e.g. patients inclined to use cannabis might differ in other ways). Also, what is the optimal formulation? Some findings (like the nabilone studies) suggest THC is key for nightmares, whereas anecdotal reports of CBD reducing anxiety indicate a role for CBD. It's plausible a combination is best, but dosing and ratio need elucidation. Another gap is functional outcomes – while symptoms improve, does cannabis actually restore better daily functioning or just numb the distress? And if the latter, is it masking symptoms without processing trauma (which therapy aims to do)?

Future Directions: Fortunately, research momentum is increasing. A multi-site phase 2 trial of a THC/CBD oral formulation in PTSD is underway, as are studies combining psychotherapy with cannabinoids (like CBD-enhanced exposure therapy). There is also interest in other modulators of the endocannabinoid system, such as fatty acid amide hydrolase (FAAH) inhibitors or anandamide reuptake blockers, which could elevate the body's own cannabinoids without psychoactive effects – a strategy that might yield PTSD benefits with fewer risks. In conclusion, medical cannabis shows potential for mitigating PTSD symptoms, particularly sleep-related and hyperarousal symptoms, but careful clinical implementation and more rigorous evidence are needed before it becomes a routine treatment. It offers a novel mechanism of action distinct from existing medications, targeting the biology of fear and memory, which for some patients can be the key to reclaiming their life after trauma.

Anxiety Disorders

Background: Anxiety disorders, including generalized anxiety disorder (GAD), social anxiety disorder, panic disorder, and others, are among the most prevalent mental health conditions. Standard treatments (SSRIs, SNRIs, benzodiazepines, psychotherapy) help many but can be inadequate or cause side effects (e.g. sedation, dependence in the case of benzodiazepines). Cannabidiol (CBD), a major non-intoxicating component of cannabis, has attracted significant attention as a potential anxiolytic. Early preclinical studies and small human trials have suggested CBD can reduce anxiety without the risk of intoxication or dependence, making it particularly appealing. In contrast, THC has a biphasic effect on anxiety: low doses may be anxiolytic, but high doses often provoke anxiety and paranoia. Thus, the interest in "medical cannabis for anxiety" largely centres on CBD or balanced THC:CBD preparations, rather than high-THC cannabis. Many consumers already use low-THC/high-CBD products (like hemp-derived CBD oils) for anxiety, albeit often without medical supervision. This section will focus on clinical evidence for CBD and carefully-dosed THC in anxiety disorders.

Mechanisms: CBD's anxiolytic effects involve multiple pathways. It is a partial agonist at 5-HT_1A serotonin receptors, much like buspirone, which can induce calm and reduce anticipatory anxiety. It also indirectly influences GABAergic transmission and can modulate fear circuitry in the amygdala and hippocampus by affecting CB_1 receptors (even though CBD doesn't strongly bind CB_1, it alters endocannabinoid levels by inhibiting their breakdown). Neuroimaging studies have shown that CBD reduces activation in the amygdala and cingulate cortex during anxiety-provoking tasks, correlating with reduced subjective anxiety. THC, at low doses, may relieve anxiety through CB_1-mediated suppression of excitatory transmitters and by inducing mild euphoria/relaxation. However, above a certain threshold, THC can trigger panic via overstimulation of the amygdala or by causing autonomic arousal (e.g. fast heart rate). Therefore, dose and cannabinoid ratio are critical: a preparation rich in CBD (which can counteract some THC effects) or with minimal THC is generally considered for anxiety treatment.

Clinical Evidence – Cannabidiol: A growing body of evidence from RCTs and experimental studies suggests that CBD has anxiolytic activity:

- Social Anxiety (SAD): In a hallmark 2011 double-blind trial, a single 600 mg dose of CBD significantly reduced anxiety and cognitive impairment in people with social anxiety disorder during a simulated public speaking test, compared to placebo. CBD-treated participants had lower self-rated anxiety and discomfort in their speech performance, approaching the responses of healthy controls. Subsequent studies replicated this finding at 300 mg CBD, noting an optimal dose range (100 mg was ineffective, 300 mg effective, 600 mg sometimes with diminishing returns). A 2019 Japanese trial gave teenagers with SAD a month of daily CBD (300 mg) and found not only reduced anxiety symptoms but also that 50% of them achieved clinical remission of SAD, vs 0% on placebo. These results are very promising, indicating CBD can markedly reduce performance and social anxiety.

- Generalized Anxiety (GAD): Fewer RCTs exist specifically for GAD. However, a 2019 study in healthy volunteers with high trait anxiety showed that 300 mg CBD lowered anxiety on a simulated public speaking task (a common stress test). On the other hand, a recent trial in patients with moderate GAD symptoms did not find a significant benefit of CBD over placebo—possibly due to a low dose (150 mg) or too short duration. Some open-label evidence comes from a clinic in Colorado: in a series of 72 psychiatric patients with anxiety, CBD (25–50 mg/day) for several months was associated with anxiety score reductions in 79% of patients in the first month, which remained improved for the majority through 3 months. Sleep also improved in many. While open-label, it mirrors what patients often self-report.
- Anxiety in PTSD and others: As covered in the PTSD section, CBD might reduce anxiety associated with trauma cues. Similarly, there's interest in CBD for panic disorder and as an adjunct in OCD (to facilitate fear extinction, as mentioned). No large trials yet, but a recent meta-analysis of both clinical and preclinical data concluded "CBD shows promise in alleviating anxiety, particularly compared to placebo, with a favourable safety profile".

Clinical Evidence – THC and Whole Cannabis: Data on using THC-predominant cannabis for anxiety disorders are more cautionary. Epidemiological studies actually associate heavy cannabis use with increased risk of developing anxiety disorders in some individuals, though causality is debated. In controlled settings, low doses of THC (~2.5 mg) have been observed to transiently reduce anxiety and induce relaxation, but slightly higher doses (≥5–7.5 mg in naive users) can cause significant increases in anxiety and panic symptoms. One randomized crossover study in 2020 gave healthy volunteers THC (7.5 mg) with or without CBD and then subjected them to stress tasks. THC alone induced mild to moderate anxiety in many participants, whereas when CBD was combined with THC, the CBD attenuated THC-induced anxiety, especially in those with lower baseline anxiety. This suggests CBD can buffer some of THC's anxiogenic effects. Another placebo-controlled trial in people at clinical high risk for psychosis (who often have anxiety) found 600 mg CBD over 1 month did not significantly alter anxiety symptoms, though baseline stress of blood draws might have confounded results.

Overall, the consensus is that CBD is the primary candidate for anxiolysis, while THC's role is limited or even counterproductive beyond very low doses. Many medical cannabis preparations for anxiety use a CBD-rich, low-THC formulation (e.g. 20:1 CBD:THC).

Safety: One of CBD's attractive features is its benign safety profile. Across numerous studies, even high doses (600–800 mg in a single dose or 300 mg daily for months) did not produce serious adverse effects. Unlike benzodiazepines, CBD has no reinforcing addictive properties, and discontinuation does not cause physiological withdrawal. Mild side effects can include tiredness, light-headedness, or gastrointestinal upset. In some trials, no significant side effects were reported at all. This aligns with large trials of CBD in epilepsy where the main issues were sedation (often in combination with other sedatives) and diarrhoea. Importantly, CBD does not cause cognitive or psychomotor impairment in the way THC can, so patients can function normally. That said, a subset of individuals might find CBD ineffective or even stimulating (there are rare reports of CBD causing

irritability or insomnia, possibly due to differing neurochemistry or impurities in unregulated products).

For THC or THC-rich cannabis, safety concerns for anxiety patients include the risk of worsening anxiety or triggering panic, especially if the patient is not tolerant to THC. There is also the general risk of dependence and cognitive side effects with chronic high-THC use, which could outweigh any short-term anxiolysis. Thus, medical use of THC for anxiety is typically reserved for specific situations (e.g. acute calming of agitation at very low dose, or when CBD alone is insufficient and patient can tolerate some THC).

Limitations: Many of the CBD studies have been acute dosing trials. Fewer data exist on chronic use in clinical populations, though what exists is positive. There is also variability in dosing – effective doses in studies range from 25 mg up to 600 mg, and it's not clear what the minimum effective dose is for different anxiety disorders. Optimal dosing regimens, frequency, and long-term efficacy all need further clarification. Another limitation is that anxiety disorders are often subjective; placebo response can be high. Indeed, a meta-analysis noted that while CBD shows promise, several studies had limitations like small sample sizes and some conflicting results at different doses. For example, 100 mg CBD didn't reduce anxiety in one trial, whereas 300 mg did – pointing to a possible bell-shaped dose-response curve. More systematically, a 2022 systematic review of RCTs concluded that "despite some conflicting results, CBD appears to alleviate anxiety compared to placebo, with minimal adverse effects; however, more rigorously designed trials are needed".

Future Directions: Active research is ongoing. Several clinical trials are examining CBD for panic disorder and performance anxiety, as well as CBD as an adjunct to antidepressants in GAD. There is also interest in minor cannabinoids (like CBG, cannabigerol) or terpenes with purported anxiolytic effects (like linalool, found in lavender, which some cannabis strains contain). As for THC, microdosing strategies (e.g. ~1 mg THC co-administered with CBD) could be studied to see if they add benefit or just risk. Combination products (like CBD with a small amount of THC or CBN (cannabinol)) are being explored for insomnia with comorbid anxiety, as the sedation can complement anxiety relief at night.

In summary, medical cannabis—chiefly via CBD—holds significant promise as a treatment for anxiety disorders. The existing evidence, though not yet conclusive, is supportive of CBD's efficacy in reducing social and generalized anxiety with a good safety profile. It may offer a much-needed alternative for patients who do not tolerate or respond to standard anxiolytics. As always, more large-scale trials will be essential to fully integrate cannabinoids into anxiety disorder treatment guidelines.

Major Depressive Disorder (MDD)

Background: Depression is a mood disorder marked by persistent low mood, anhedonia (loss of interest), changes in sleep/appetite, and often suicidal ideation. Current antidepressants (SSRIs, SNRIs, etc.) take weeks to work and are ineffective in a significant minority of patients. This has led to interest in novel targets – and some have wondered whether cannabinoids could have antidepressant effects. Population data show a complex relationship: some people with depression use cannabis to "lift" their mood, but epidemiological studies more often link chronic cannabis use to higher rates of depression (though directionality and confounding factors are debated). Unlike anxiety or PTSD, depression is not commonly cited as an indication for medical cannabis in guidelines, mainly due to lack of evidence. Nonetheless, preclinical studies have indicated that modulating the endocannabinoid system can affect mood regulation. For instance, blocking CB_1 receptors induces depressive-like behaviour in animals, whereas enhancing endocannabinoid signalling can produce antidepressant-like effects in rodent models (e.g. increasing anandamide levels leads to stress resilience). This suggests the endocannabinoid system plays a role in mood, but translating that into a cannabis-based treatment for depression has proven challenging.

Mechanisms: Several mechanisms have been proposed by which cannabinoids might influence depressive symptoms. Endocannabinoids modulate monoamines (serotonin and norepinephrine) in the brain; THC acutely increases dopamine release (hence euphoria), which could temporarily alleviate anhedonia. CBD interacts with serotonin receptors and may promote neurogenesis in the hippocampus (a property shared by classical antidepressants). Additionally, cannabinoids have anti-inflammatory and neuroprotective effects, and chronic inflammation is linked to some cases of depression. There's also overlap between the endocannabinoid system and the hypothalamic-pituitary-adrenal axis – in theory, cannabinoids might help normalize stress hormone dysregulation seen in depression. However, one must consider that THC's psychoactive effects can include apathy, reduced motivation, and emotional blunting with heavy use, which could actually worsen depressive symptoms or anhedonia in the long run. Indeed, reviews note evidence that THC might exacerbate depression in some cases, whereas CBD (with its anxiolytic and antistress effects) could have a mild positive effect on mood.

Clinical Evidence: High-quality clinical research specifically on cannabis for depression is extremely limited. There have been no major RCTs of cannabis or cannabinoids as a primary treatment for MDD. What we know comes from smaller studies and indirect evidence:

- Synthetic THC analogues in cancer/HIV patients: Some trials of dronabinol (THC) in patients with AIDS or cancer (where it's used for appetite) incidentally measured mood. They generally found no significant antidepressant effect; if anything, some patients had mood improvement secondary to better appetite/sleep, but others had dysphoric reactions. A systematic review in 2019 concluded "no benefit for depression from high-THC therapeutics" based on preliminary research. This suggests THC is not an effective antidepressant and could be destabilizing.

- CBD for depression: Direct evidence is sparse. One small open-label study in 2020 gave CBD to a handful of patients with depression and noted improvements in Beck Depression Inventory scores, but without a control group it's hard to ascribe causality. A case series of bipolar depression treated with CBD did not find clear benefits. Notably, a large trial of CBD in schizophrenia found it improved anxiety but not depressive symptoms. Thus, CBD's impact on pure depression is unclear, though its anti-anxiety effect can indirectly improve mood.
- Epidemiological observations: Some longitudinal studies (e.g. a large survey of adolescents) found that baseline cannabis use was associated with a modestly higher risk of developing depression later (odds ratio ~1.3). While this does not prove causation (common risk factors might lead to both cannabis use and depression), it raises caution that cannabis is not protective for mood in the population at large. Conversely, among people already depressed, those who use cannabis often report using it to cope or escape. Surveys of medical cannabis users list "depression/mood" among common reasons (about 34% of one sample), but we don't have rigorous data that their depression improved as a result.
- Animal to human translation issues: In rodents, certain cannabinoids show antidepressant-like effects (e.g. low-dose THC or increasing endocannabinoid tone can reduce immobility in the forced swim test, a proxy for antidepressant activity). However, these models don't always predict human outcomes, as we saw with THC not yielding clear antidepressant effects clinically.

Safety Considerations: In depressed individuals, especially those with suicidal ideation, introducing cannabis has to be done cautiously. THC can acutely elevate mood (euphoria) but also can cause paradoxical dysphoria or anxiety in some. There's also a risk it could worsen amotivation – depressed patients already struggle with energy and drive, and heavy cannabis use is known to cause amotivational syndrome in some users, potentially exacerbating this aspect of depression. Importantly, cannabis use can become a form of avoidance (self-medicating to numb emotional pain), which might impede engaging in therapy or addressing root issues. Dependence risk is there: depressed individuals may be more prone to developing cannabis use disorder as they chase mood relief. Additionally, THC and antidepressants can interact in unpredictable ways (though no dangerous pharmacological interactions are known, the psychoactive effects might complicate assessment of antidepressant efficacy or side effect attribution).

On the other hand, one must note that CBD is generally safe and well-tolerated, so trials of CBD in depression are ethically feasible. The main safety concern for CBD would be if it's used in lieu of proven treatments without evidence, potentially leaving severe depression undertreated.

Current Position: At this time, no medical guidelines recommend cannabis or cannabinoids for treating MDD, given the lack of evidence and potential risks. A 2020 overview explicitly found "no clinical evidence supporting cannabis as an antidepressant", and in fact suggested avoiding high-THC products in people with mood disorders due to risk of worsening depression or precipitating psychosis. There is a possibility that components of cannabis other than THC might have mood benefits – for example, some

research has looked at CBC (cannabichromene) or terpenes with antidepressant-like activity in animals. But these remain speculative.

Future Directions: Despite disappointing data so far, the door isn't completely closed. Targeted research into the endocannabinoid system in depression is ongoing. One hypothesis is that endocannabinoid deficiency might contribute to chronic depression in some individuals; if true, strategies to boost endocannabinoids (like inhibiting FAAH to increase anandamide) could be novel antidepressants. There was a trial planned using a FAAH inhibitor in mood disorders, but earlier safety issues in unrelated trials have slowed that field. Another area is inflammation-related depression: since cannabinoids have anti-inflammatory effects, perhaps patients with high inflammatory markers might benefit from adjunctive CBD (similar to how anti-inflammatory drugs are being tested for depression). Additionally, psychedelic-assisted therapy is being explored in depression, and while different pharmacologically, it reflects a broadening interest in non-traditional psychoactive substances for refractory cases. In that landscape, it's conceivable that a carefully calibrated cannabinoid regimen could one day find a role as an adjunct – for instance, using CBD to manage anxiety and improve sleep in depression, which could support overall recovery.

In summary, medical cannabis is not an evidence-based treatment for MDD at this time. High-THC products may do more harm than good for mood, and while CBD is safe, its efficacy in lifting depression is unproven. Patients with depression who seek cannabis should be counselled ›about these uncertainties and the importance of continuing with established treatments. Future rigorous studies are needed to determine if any cannabinoid-based interventions can reliably improve depressive symptoms, or if the role of cannabis in depression will remain limited to anecdotal and individual cases.

Insomnia

Background: Insomnia – difficulty falling or staying asleep – is a widespread condition that can be primary or secondary to other disorders (like anxiety, PTSD, chronic pain, etc.). Cannabis has a long history of use as a sleep aid, and many individuals report using marijuana or CBD in the evenings to improve sleep. The sedative effects of certain cannabis strains (particularly so-called "indica" varieties high in sedating terpenes and moderate THC) are well known anecdotally. Prior to modern sleeping pills, cannabis tinctures were used in the 19th century for insomnia. With the advent of medical cannabis, insomnia has re-emerged as a leading indication: surveys show a significant proportion of medical users list insomnia or poor sleep as a reason. Scientifically, the endocannabinoid system is involved in regulating sleep-wake cycles, and both THC and CBD influence sleep architecture (though in different ways). This makes insomnia one of the more plausible targets for cannabinoid therapy.

Mechanisms: THC tends to have a dose-dependent sedative effect. At the physiological level, activating CB_1 receptors can induce sleep by suppressing arousal pathways in the brain. THC decreases sleep latency (time to fall asleep) in many people and can increase deep slow-wave sleep while shortening REM sleep (hence reducing dreaming). For someone with insomnia characterized by difficulty falling asleep or with PTSD nightmares, these effects are beneficial. CBD's effects on sleep are more complex – low doses of CBD may be mildly alerting, while higher doses (≥100–150 mg) have been reported to increase total sleep time and reduce nighttime awakenings in some studies. CBD may act on serotonin and GABA systems to promote relaxation and indirectly improve sleep by reducing anxiety. Additionally, terpenes like myrcene (found in many cannabis strains) have sedating properties and might contribute to whole-plant cannabis sleep effects. Overall, a combination of THC and CBD might offer both sleep initiation (from THC) and sleep maintenance/stability (from CBD's anxiolytic effect preventing 3 AM wake-ups).

Clinical Evidence: The evidence for cannabinoids in insomnia has strengthened recently with controlled trials:

- Randomized Controlled Trials: A 2022 double-blind crossover RCT in adults with chronic insomnia tested a nightly THC/CBD oil (Entoura 10:15, containing 10 mg/mL THC and 15 mg/mL CBD) versus placebo. Over 2 weeks on the active oil, participants experienced significant improvements in both sleep quality and duration. Objective measures using sleep trackers showed that total sleep time increased (particularly light sleep stage by ~21 minutes) and sleep quality scores improved by up to 80% relative to baseline. Midnight melatonin levels also rose in the cannabis condition, suggesting better alignment of circadian signalling. These improvements were statistically significant, and participants reported better next-day functioning. No serious adverse effects occurred; a few had mild grogginess. This study provides solid evidence that a THC/CBD combination can effectively treat insomnia.
- Another RCT (2021) explored CBN (cannabinol) – a cannabinoid reputed to be sedating – in combination with CBD for insomnia. It found that CBN+CBD improved

some sleep parameters (like time spent asleep) compared to placebo, whereas CBN alone did not significantly differ from placebo. This suggests synergy between cannabinoids, or simply that CBD was the main active agent and CBN added little.

- Open-label and Observational Data: In a large retrospective analysis of medical cannabis patients, those using it for insomnia reported high satisfaction, with the majority reducing or stopping other sleep medications. Formulations containing at least some THC generally fared better for sleep induction. An observational study in 2019 noted that PTSD patients who used cannabis slept longer and more deeply than those who did not. Another case series showed improvement in sleep latency and fewer nighttime awakenings with CBD-rich oil (25–50 mg CBD) nightly.
- Indirect evidence: Many trials in other conditions documented improved sleep as a secondary outcome. For example, in chronic pain trials, patients on nabiximols or dronabinol often reported better sleep than those on placebo. In anxiety studies, improved sleep scores were noted with CBD. These hints support a broad sleep-promoting effect of cannabinoids across different populations.

Safety and Side Effects: For insomnia, one advantage of cannabinoids (especially compared to benzodiazepine or Z-drug hypnotics) is the low risk of fatal overdose and relative preservation of sleep architecture (aside from REM). THC, however, can cause next-day drowsiness, especially if dosing is high or taken late at night. In the crossover RCT, they carefully titrated dose (0.2–1.5 mL of oil) to effect, and no significant next-day impairment was seen. Another study explicitly tested next-day cognitive function after a night dose of THC/CBD oil and found no significant residual impairment on a battery of tests. Nonetheless, individuals can vary; some might experience a "hangover" effect, so caution with activities like driving the next morning is advised until one knows their response. Other side effects can include dry mouth and increased appetite (problematic if trying to avoid nighttime snacking).

Dependency is a consideration: using high-THC cannabis nightly could lead to tolerance, where over time the sleep benefit diminishes, and one might even get rebound insomnia if they skip a dose. However, some studies suggest that at least over a few weeks, improvements persist. Withdrawal from chronic heavy use can cause transient insomnia, so if used therapeutically, one would manage this risk by possibly tapering or using intermittently. Notably, CBD-dominant preparations have no known dependency potential and can be stopped without withdrawal, making them attractive for long-term use if effective.

Regulatory Status: Insomnia is often included in the list of conditions for which medical cannabis can be recommended in jurisdictions where it's legal, especially if it's related to another qualifying condition (like PTSD or chronic pain). However, clinicians are sometimes hesitant because of the historical stigma around prescribing a "drug of abuse" for sleep. But the emerging evidence base is shifting this perspective.

Limitations of Current Research: While results are positive, most RCTs have been relatively short (2–4 weeks). Long-term efficacy data (beyond a few months) is lacking. We don't know if tolerance might erode benefits or if there are any subtle effects on sleep architecture long-term (like suppression of REM might or might not be harmful; chronic

REM suppression with THC could potentially affect memory consolidation or mood, though this is speculative). Also, insomnia has many subtypes – initial insomnia (trouble falling asleep) vs maintenance insomnia (waking at 3 AM). It appears cannabinoids help both to some degree, but more so with sleep initiation (THC's sedative effect helps one fall asleep faster, which was reflected in patient reports). CBD's impact on maintenance needs more data – there were suggestions that it reduced nighttime awakenings, likely by reducing anxiety and pain that wake people.

Future Directions: Further studies could compare cannabinoid therapy head-to-head with standard hypnotics for efficacy and safety. Given the public's interest, it's important to know, for example, if CBD or a THC/CBD combo could be as effective as zolpidem or trazodone for chronic insomnia. Also, research into personalized approaches: some may do fine with CBD alone (particularly if anxiety is the main culprit of their insomnia), while others may require some THC. Identifying the minimal THC needed for effect would maximize safety. Another interesting angle is sleep apnoea – one study showed THC (dronabinol) reduced apnoea index modestly, positing a role for cannabinoids in sleep-breathing disorders, though that's separate from insomnia per se.

In conclusion, medical cannabis (especially combined THC/CBD formulations) has demonstrated efficacy in improving insomnia symptoms in recent controlled trials. Patients get to sleep faster, sleep longer, and rate their sleep as higher quality on cannabinoids compared to placebo. The therapy is generally well-tolerated, with careful dosing needed to avoid next-day grogginess. These findings validate some of the long-standing patient claims and indicate that cannabinoid-based medicines could become a part of the toolbox for treating chronic insomnia, particularly when conventional treatments fail or are contraindicated.

Eating Disorders (Anorexia Nervosa and Others)

Background: Eating disorders like anorexia nervosa (AN) and bulimia nervosa (BN) are complex conditions involving both psychological and physiological dysregulation. In anorexia, an intense fear of gaining weight and body image distortion lead to self-starvation and often severe malnutrition. There is no highly effective pharmacotherapy for anorexia; treatment mainly relies on nutritional rehab and psychotherapy, but mortality remains high. One hallmark of AN is appetite loss or suppression of hunger cues – patients often report not feeling hunger normally. Given that cannabis is known to stimulate appetite ("the munchies"), it has been considered as a potential tool to help weight restoration in anorexia or to treat associated symptoms (like anxiety). Dronabinol (synthetic THC) is already approved to treat AIDS-related cachexia and chemotherapy-induced appetite loss. In principle, it could similarly stimulate appetite in anorexia patients. Additionally, there is overlap in neural circuits of reward and motivation that could be dysregulated in eating disorders, where endocannabinoid modulation might help (for example, endocannabinoid dysfunction in the insula and hypothalamus has been observed in AN). Bulimia and binge-eating disorder involve episodes of excessive eating often followed by guilt; theoretically, cannabinoids might either help by reducing anxiety that triggers binges or could worsen by increasing food intake – it's not straightforward. Most research to date has focused on anorexia nervosa.

Mechanisms: THC strongly stimulates appetite via CB_1 receptors in the hypothalamus, increasing the release of hunger hormones like ghrelin and enhancing the pleasure of eating by dopamine release in reward pathways. Endocannabinoids normally rise when we're food-deprived to prompt feeding – AN patients, paradoxically, might have alterations in this system (some studies show upregulation of brain cannabinoid receptors in AN, possibly as a compensatory mechanism). By giving an exogenous cannabinoid (THC), we might kick-start the drive to eat. Improved appetite and enjoyment of food could assist weight gain. CBD is not known to stimulate appetite (it may even reduce it in some cases), so it's mainly THC that's of interest here. Another angle is anxiety and obsessive features of anorexia: some anorexic patients have intense anxiety around eating and rigid obsessive behaviours. A small calming effect of cannabinoids might ease those psychological barriers to intake. Furthermore, in chronic anorexia, there are changes in metabolic and hormonal systems – cannabinoids might help regulate those (for instance, THC can lower elevated cortisol levels, which are often high in anorexia). However, it's critical to note that treating anorexia is not just about inducing hunger; the psychological component is huge, and any pharmacologic aid must be part of a broader treatment plan.

Clinical Evidence: There have been a few controlled trials of dronabinol (synthetic THC) in anorexia nervosa:

- A randomized placebo-controlled trial in 2014 with 25 adult women with chronic anorexia tested dronabinol 2.5 mg twice daily vs placebo for 4 weeks (with a crossover design). The primary outcome was weight gain. Results: Dronabinol was associated with a small but significant weight gain – on average, +0.73 kg more than placebo over 4 weeks. While modest, this was statistically significant ($p<0.01$) and

clinically relevant given how hard it is for AN patients to gain weight. About 50% of patients on dronabinol were rated as "responders" with noticeable weight increase vs ~10% on placebo. There was no serious adverse events; importantly, no psychotropic high was reported at this dose in the underweight population. The medication was well tolerated.

- Secondary outcomes in that trial included measures on the Eating Disorder Inventory (EDI-2) for body image and drive for thinness. Dronabinol did not significantly change the core psychopathology scores (e.g. body dissatisfaction remained essentially the same). This indicates that while THC may help with weight gain, it's not addressing the cognitive distortions of anorexia – which is expected, as no drug really does that well.
- Another pilot study (2017) extended dronabinol treatment up to 8 weeks in severe enduring anorexia and found similarly that some weight gain was achieved without major side effects. A curious finding in one was that physical activity slightly increased with dronabinol (perhaps as patients had more energy), which could counteract some calorie gains.
- Bulimia/Binge eating: There's very limited formal research. One trial in the Netherlands tried tetrahydrocannabinol in bulimia and found no improvement in binge-purge frequency. However, more recently, CBD has been hypothesized as a treatment for binge eating because of its role in impulse control and anxiety; an Israeli group is running a trial with CBD and dronabinol in binge eating disorder (early phases). No results yet to validate this.
- Cachexia vs Anorexia nervosa: It's worth noting that dronabinol is effective in increasing appetite and weight in AIDS or cancer cachexia, but anorexia nervosa is different in that the limitation is psychological as much as physiological. Still, the modest success in weight gain suggests it can be a helpful adjunct.

Safety and Tolerability: Malnourished anorexia patients are physically fragile – bradycardia, hypotension, and brain atrophy can occur. Thus, a concern might be whether THC could cause cardiovascular issues (tachycardia or orthostatic hypotension) in these patients. In the trials, no severe adverse events occurred. Some patients reported feeling a bit more relaxed or "spaced out," but the low dose used did not produce the intense high that recreational use might. There were no reports of abuse or loss of control – which is notable as one might worry about giving a potentially addictive substance to psychiatric patients, but anorexia patients are generally not pleasure-seeking and have low addiction rates to substances (their addiction is more to not eating). In fact, compliance was good. Over longer periods, more data would be needed to ensure there's no cognitive impairment; but in severe anorexia, cognitive function is already impaired by starvation, and any improvement in nutrition should outweigh subtle cognitive effects of THC.

One ethical concern is whether giving a drug that can cause euphoria is problematic in a population that might then see it as a weight-loss workaround (e.g., thinking "if I take this pill and get hungry and eat, at least I enjoy something"). However, these theoretical issues haven't manifested as major problems in the studies done.

Limitations: The weight gain observed was modest – 0.7 kg in a month is progress, but anorexia patients often need to gain 10–20 kg to reach a healthy weight. THC is not a cure;

it's an adjunct that might make the refeeding process slightly easier. It did not improve the core psychological aspects (no change in body image distortion). Thus, any use of medical cannabis in anorexia would be as a supportive measure to assist alongside therapy and supervised nutritional rehabilitation. Also, those trials were in adults with chronic AN. It's unclear if adolescents (the typical onset age) would benefit similarly or if cannabis use in a developing teen with an eating disorder would have different effects. Given the caution around exposing adolescents to THC, that's an open question.

Future Directions: More research could explore if higher doses or longer duration of cannabinoid therapy yield more substantial weight gain, or if combining cannabinoids with other appetite stimulants (like mirtazapine or olanzapine, which are sometimes used in AN) has an additive effect. As for bulimia or binge-eating, it might be that CBD could reduce binge frequency by lowering anxiety and compulsivity without increasing appetite, but that remains to be studied. Conversely, THC likely isn't suitable for bulimia since increasing appetite might worsen binges. Another possible area is anorexia-related mood symptoms: many anorexia patients are anxious or obsessive; perhaps cannabis could help with those and indirectly improve intake.

In summary, medical cannabis (specifically THC) has shown a modest benefit in anorexia nervosa by inducing weight gain in clinical trials, with one study finding ~0.7 kg greater gain over placebo in 4 weeks. This was achieved without significant side effects. The therapy did not change the distorted cognitions of the illness but helped address the physical component of starvation by boosting appetite. For other eating disorders, evidence is minimal, but mechanistically cannabinoids may hold some potential (CBD for binge eating, perhaps). Any use of cannabinoids in these disorders must be carefully integrated into a comprehensive treatment plan. Encouraging eating behaviour in anorexia is lifesaving, and cannabinoids appear to be one tool that can assist in that mission, albeit modestly.

Personality Disorders (Focus on Borderline Personality Disorder)

Background: Personality disorders (PDs) are enduring patterns of inner experience and behaviour that deviate markedly from cultural expectations, with onset in adolescence or early adulthood. There are various types (borderline, antisocial, narcissistic, etc.), but borderline personality disorder (BPD) – characterized by emotional instability, impulsivity, self-harm, and unstable relationships – is both common and notoriously challenging to treat. No specific medications are approved for BPD; treatment is primarily psychotherapy (like DBT). Patients often have comorbid conditions (depression, PTSD, substance use) that are treated pharmacologically. Some individuals with BPD use cannabis, possibly to self-medicate anxiety or anger, though uncontrolled use can exacerbate impulsivity or dissociation in others. Until recently, there has been virtually no research on cannabinoids as a treatment for personality disorders. However, the growing understanding of the endocannabinoid system's role in emotional regulation and stress response has led to preliminary exploration.

Rationale and Mechanisms: BPD is marked by difficulty regulating emotions and coping with stress; the endocannabinoid system helps regulate stress responses, fear extinction, and serotonin signalling, which are relevant to BPD symptoms. For example, low endocannabinoid levels have been associated with increased aggression and stress reactivity in animal studies. THC could hypothetically reduce anger outbursts or affective instability by dampening amygdala reactivity and inducing calm (similar to how some patients report using cannabis to "take the edge off" their emotions). CBD might reduce anxiety and paranoia (transient psychotic-like symptoms can occur in BPD under stress) and improve insomnia, which in turn can stabilize mood. Additionally, many with BPD have co-occurring PTSD or complex trauma histories – as discussed, cannabinoids can help PTSD symptoms, which might indirectly improve BPD presentations. There's also an interesting angle: BPD patients often have a hyperactive HPA (stress hormone) axis; endocannabinoids help "turn off" the stress response, so augmenting that system might normalize stress hormone release.

Emerging Evidence: While still in infancy, there has been a recent case series and a narrative review (2022) examining cannabis-based medicinal products (CBMPs) in emotionally unstable (borderline) personality disorder. In this case series, seven patients with severe BPD were prescribed cannabis-based medicines containing both THC and CBD (in varying ratios individualized to the patient) for one month. Results were promising: six of the seven patients reported an improvement in their BPD symptoms, and none reported adverse side effects. Improvements included reductions in anxiety, better emotional stability, and less impulsive aggression. The authors noted substantial improvement in overall functioning in several cases. This is a tiny sample, but it represents the first published medical evidence suggesting cannabinoids may help mitigate symptoms of BPD. Alongside the case series, a narrative review of literature found enough theoretical and indirect evidence to justify considering CBD (with some THC) in managing severe mood instability, though it emphasized that controlled trials are needed.

Beyond this, evidence is anecdotal: some individuals with BPD on internet forums or small surveys have reported that CBD oil helps with their anxiety, dissociative episodes, or insomnia, making them feel more grounded. Others warn that high-THC cannabis can worsen paranoia or loss of control for BPD sufferers. Thus, it's not universally beneficial and likely depends on the formulation and patient.

Safety Considerations: BPD patients have elevated risk for substance abuse, but interestingly their drug of choice is often not cannabis (alcohol or stimulants are common). If a physician were to prescribe cannabinoids for BPD, careful monitoring for dependency or misuse would be needed given the impulsivity trait. However, in the case series, because these were medically supervised prescriptions (some likely oral solutions or vaporizable formulations from a clinic), misuse was not observed, and side effects were minimal. No adverse effects suggests that with appropriate THC:CBD ratios (perhaps leaning towards higher CBD to mitigate intoxication), patients did not experience negative reactions. THC in BPD could potentially trigger dissociation or transient psychotic symptoms if too high; thus a low-THC, high-CBD approach has been suggested as optimal. Indeed, some recommend starting with CBD-dominant products for personality disorder patients to avoid destabilizing effects.

A unique ethical aspect is whether using a psychoactive substance in a personality disorder might be avoiding the psychological work needed in therapy. But if the substances genuinely stabilize mood or reduce symptom severity, they could enable better engagement in therapy. For example, if cannabis reduces a patient's chronic anxiety and insomnia, they may be more receptive to psychotherapy and less prone to emotional crises that interrupt treatment.

Limitations: The evidence so far is extremely limited (open-case series). We cannot generalize to all PDs or even all BPD patients. The placebo effect in subjective symptom reporting is possible; without a control, it's hard to gauge how much was pharmacological. BPD symptoms also fluctuate naturally, so improvement could be coincidental. Moreover, we don't know which specific symptoms improved most – the case series reported global "improvement," but did it mostly help anxiety and insomnia, or did it actually reduce classic BPD features like fear of abandonment or unstable self-image? Likely the improvements are in mood stabilization, reduced anger, and better sleep, as those are areas cannabinoids are known to affect.

Future Directions: There is clear room (and need) for formal studies. A randomized controlled trial of CBD (with maybe a small THC component) in BPD could be done to quantify effects on mood lability, impulsivity, and dissociative symptoms. Biological studies could examine if BPD patients have differences in endocannabinoid levels or receptor polymorphisms that cannabinoids normalize. Also, since BPD often overlaps with PTSD, one could see if the benefits observed are actually due to treating undiagnosed PTSD symptoms within BPD patients – in which case focusing on those might be key.

Other personality disorders: There's virtually no data, but one might speculate antisocial PD – probably not a focus due to their different issues and potential for substance misuse. Schizotypal PD (which has psychotic-like symptoms) would likely not be suitable for THC

due to psychosis risk, although CBD (which has antipsychotic properties) might help anxiety in those patients.

In summary, the notion of using medical cannabis in personality disorders is novel and evidence is preliminary but intriguing. The early case series suggests that a controlled environment and balanced THC/CBD products can provide tangible symptom relief in borderline personality disorder. This could herald a new adjunctive approach for a condition with few pharmacological options. However, robust research is needed to confirm efficacy, determine ideal formulations (most advise combining THC+CBD tailored to patient response), and ensure safety given the population's vulnerabilities. Until then, any use should be highly individualized and monitored by clinicians experienced with both BPD and cannabinoid medicine.

Discussion

Across these diverse conditions, the role of medical cannabis ranges from promising in targeted symptom relief to unsupported or potentially risky in others. Several overarching themes and considerations emerge from the evidence:

1. Symptom-Specific Efficacy vs. Core Disorder Impact: Cannabinoids often show efficacy in alleviating certain symptoms rather than curing the underlying disorder. For example, in ASD they reduced aggressive behaviours and improved sleep but did not improve core social deficits. In PTSD, they markedly reduced nightmares and insomnia, though overall recovery still relies on therapy for trauma processing. This pattern suggests that medical cannabis might be best conceptualized as a symptom-targeted adjunct – akin to how analgesics treat pain without fixing its root cause. Clinicians considering cannabinoid therapy should define clear target symptoms (e.g. tics, anxiety, insomnia) and measure success in those domains, rather than expecting global remission of the disorder.

2. THC vs. CBD – Balancing Efficacy and Safety: THC is the component most linked to direct symptomatic effects in conditions like Tourette's (tic suppression), anorexia (appetite stimulation), and nightmares in PTSD. However, THC also carries the greatest risk of side effects: cognitive impairment, anxiety, psychotomimetic effects, and dependence. CBD, conversely, has a strong safety profile and broad anxiolytic and anti-inflammatory properties, but by itself has more modest or mixed clinical results (notably effective for anxiety, possibly helpful in autism, but not clearly antidepressant). Many successful studies used combinations – harnessing THC's potency while mitigating downsides with CBD. This suggests an important principle: optimal therapeutic benefit may come from balanced cannabinoid formulations rather than isolated compounds. Future prescribing will likely involve specifying THC:CBD ratios tailored to each condition (e.g. high-CBD, low-THC for anxiety or BPD to avoid exacerbating symptoms, versus moderate THC for Tourette's tics where that receptor activation is needed). The concept of the "entourage effect" (synergy between cannabinoids and terpenes) might also explain why some whole-plant extract trials (like in insomnia) succeeded where single-molecule studies sometimes did not – minor cannabinoids and terpenes could be contributing.

3. Heterogeneity of Patient Response: A recurring observation is that responses to medical cannabis are variable. Some ADHD patients report better focus on cannabis, others experience worsened distraction. Some PTSD patients find immense relief, while a few feel more paranoid or have symptom exacerbation. This variability likely stems from individual differences in endocannabinoid system genetics, prior cannabis tolerance, and subtype of the disorder. For instance, an OCD patient with concurrent anxiety might benefit (since cannabis relieves anxiety-driven obsessions), whereas one with primarily perfectionism and mental rituals might see less change. Similarly, an autistic child with epilepsy and aggression might improve on CBD (given known anti-seizure and calming effects), whereas a high-functioning adult with autism might find little effect on social engagement.

Hence, patient selection is critical – those with prominent anxiety, sleep disturbance, or stress-reactive components to their illness appear to derive more benefit from cannabinoids. It will be important for future research to identify predictors of response (biomarkers or clinical features) to guide personalized use of medical cannabis.

4. Study Limitations and Quality of Evidence: A major limitation in this field is that much evidence comes from open-label studies, small RCTs, or retrospective analyses. Many studies have short durations (weeks, not months or years). This raises questions about long-term efficacy and safety – e.g. do Tourette's patients maintain tic suppression over years without needing ever-increasing doses? Does long-term cannabis use for PTSD impact cognitive function or relapse rates? Additionally, many trials had difficulties with blinding because psychoactive effects can reveal treatment allocation (potentially exaggerating placebo effects for those who feel "high"). Another issue is publication bias: positive studies are often more likely to be reported than negative ones, which can skew perceived efficacy. For example, initial excitement about cannabis in ADHD may have been tempered by the negative RCT result (no significant improvement), but that negative finding gets less public attention. Researchers and clinicians must interpret current findings with caution, acknowledging these evidence gaps.

5. Regulatory and Legal Landscape: Over the last decade, legal barriers to cannabis research have slowly begun to lift. The legal status of cannabis varies widely – from strict prohibition federally in some countries (which complicates research and prescribing) to full medical legalization in others. This patchwork affects patients' access and the feasibility of clinical trials. In places where cannabis is Schedule I (highly restricted), obtaining funding, approval, and standardized study drug can be arduous. Ethical considerations also stem from this: patients may obtain and use cannabis on their own (self-medicating) if physicians cannot prescribe or even advise due to legal issues. This reality underscores the need for clear regulatory pathways to study and, if warranted, prescribe medical cannabis for these conditions safely. Encouragingly, countries like Canada, Israel, and parts of Europe have been frontrunners in both research and compassionate use programs, especially for conditions like PTSD and autism. Regulators are increasingly open to cannabinoid-based pharmaceuticals – for instance, the FDA approved CBD (Epidiolex) for epilepsy, showing that cannabinoid medicines can meet safety and efficacy standards in certain indications. Similar rigorous development is needed for psychiatric indications.

6. Ethical Considerations in Vulnerable Populations: Several conditions discussed involve children or adolescents (ADHD, ASD, Tourette's often onset in youth; personality disorders and eating disorders often start by adolescence). Using a psychoactive substance in developing brains raises ethical questions. Potential impacts on executive function, IQ, or increased risk of later substance use need to be carefully weighed. So far, paediatric trials (like those in autism or refractory epilepsy overlapping with autism) have not flagged major developmental issues, but sample sizes are small, and follow-up is short. Ethically, one must consider the severity of the condition: for a non-verbal autistic child with self-injurious behaviour, trying CBD oil under medical supervision might be justified despite unknowns, whereas giving a teenager with mild anxiety a cannabis prescription might not be, given alternative treatments and the risk profile. Another ethical aspect is informed

consent: patients (or parents) must be thoroughly educated on the experimental nature of this therapy, realistic expectations, and the need to continue with established treatments (e.g. not abandoning therapy or necessary medications).

7. Risk of Misuse and Need for Monitoring: Introducing medical cannabis into psychiatric care brings the risk that some patients could misuse it, intentionally or unintentionally. For instance, someone with PTSD might escalate their dose chasing greater numbing of emotions, potentially leading to a use disorder. Particularly in those with history of substance abuse, caution and strict monitoring are needed. Strategies like dispensing through a pharmacy with limited quantities, using non-smokable forms (to emphasize medical use over recreational association), and regular follow-up to assess for signs of dependency or cognitive side effects are prudent. Urine drug screening might even be used in some programs to ensure patients adhere to prescribed formulations rather than adding illicit high-THC cannabis.

8. Interaction with Psychotherapy: An interesting discussion point is how cannabinoids might interact with ongoing psychotherapy. In PTSD, some propose that using cannabinoids (especially CBD) could enhance therapy by reducing avoidance and hyperarousal, thus allowing patients to engage more with traumatic memories during sessions. Conversely, one could worry that if a patient uses cannabis to modulate their emotions, they might become less inclined to develop coping skills or face difficult feelings in therapy (essentially using the drug as an emotional crutch). The ideal scenario is integration: for example, a patient with BPD who has intense nightly anxiety might take a CBD-rich product in the evening to sleep better, which in turn makes them more stable and reachable in daytime therapy, but they still work on emotion regulation skills without being intoxicated during the day. Coordination between prescribers and therapists is key to ensure that cannabinoid use complements rather than hinders psychological treatment goals.

9. Medical Cannabis vs. Standard of Care: In conditions like depression or OCD where first-line treatments exist and are effective for many, medical cannabis should not be considered until those proven therapies have been tried (and in combination, can still be continued if cannabis is added). In refractory cases, cannabinoids might represent a novel mechanism to try. On the other hand, in conditions like Tourette's or PTSD where existing meds are limited or carry heavy side effects, cannabinoids might soon be considered alongside other second-line options in guidelines, given emerging supportive evidence. It's telling that some veterans' organizations and psychiatric bodies are now calling for rescheduling of cannabis to facilitate research because patient use is outpacing our evidence, and they want to ensure safety and proper guidance.

10. Standardization and Dosing Challenges: Unlike typical pharmaceuticals, medical cannabis comes in many forms (oils, capsules, flower for vaporization, etc.) and potencies. This can lead to inconsistent dosing and outcomes. One patient's 5 mg of THC might be from a very different source or co-administered with different terpenes than another's. To move forward, standardization is necessary – the use of specific, well-characterized products in research will allow replication and clearer guidelines (e.g. "CBD 300 mg daily" or "THC-CBD 1:1 spray up to X sprays/day"). Encouragingly, trials like the insomnia RCT

used a specific product and measured blood levels, etc., providing a model . Physicians will need education on how to dose medical cannabis, which is a new skill set (titrating to effect, understanding ratios).

In light of these points, a cautious but open-minded stance is warranted. The discussion within the psychiatric field is shifting from “is cannabis simply good or bad?” to “under what circumstances might cannabinoids be beneficial, and how do we maximize benefit/risk ratio?”. The onus is on ongoing and future research to address the many unanswered questions.

Conclusion

Medical cannabis is gaining recognition as a potential therapeutic agent across a spectrum of psychiatric and neurodevelopmental disorders, though its application must be nuanced and evidence-driven. Summarizing the current state:

- ADHD: Cannabis use is prevalent among ADHD patients, yet no robust evidence supports it as an effective treatment. A single small RCT found no significant improvement in ADHD symptoms with a THC/CBD spray, and systematic reviews conclude the impact of cannabis on attention and impulse control is inconclusive or negative. Given ADHD's vulnerability to substance misuse, cannabis is not recommended as therapy at this time, though further research may clarify if certain adult subsets benefit.

- Autism Spectrum Disorder: Cannabidiol-rich cannabis has shown promise in managing associated symptoms of ASD, such as aggression, hyperactivity, and sleep problems. Parents of children with severe autism have reported meaningful improvements in quality of life with CBD-enriched extracts. However, effects on autism's core social deficits are unclear, and current evidence derives from open-label studies and a few small RCTs. The therapy appears relatively safe in the short term, and ongoing trials will inform optimal dosing and long-term safety. Medical cannabis is emerging as a consideration for refractory behavioural issues in ASD, with cautious optimism pending stronger evidence.

- Tourette's Syndrome: Here the data are comparatively strong – THC-containing cannabis can significantly reduce tic severity in severe Tourette's. Several clinical trials (including a recent rigorous RCT) have demonstrated tic improvements and some comorbid OCD/anxiety relief with cannabinoids, with manageable side effects (primarily sedation or mild cognitive slowing). Medical guidelines are beginning to acknowledge cannabinoids as a second-line option for refractory Tourette's, especially when standard medications fail or are not tolerated. Still, treatment should be closely supervised by a specialist due to dosing complexities and psychiatric comorbidities.

- OCD: Preliminary evidence suggests short-term OCD symptom reduction with cannabinoids, particularly a reduction in compulsive behaviours and anxiety immediately after cannabis use. The concept of using cannabinoids as an adjunct to exposure therapy is intriguing but unproven. Given the lack of controlled trials, cannabinoids for OCD remain experimental. They may be considered in severe, treatment-resistant cases on a compassionate basis, targeting acute anxiety/insomnia, but always with caution that standard therapies (SSRIs, CBT)

remain first-line. More research is needed to determine if the observed benefits can translate into sustained improvement.

- PTSD: Many patients with PTSD report substantial symptom relief from cannabis, and emerging studies validate some of these claims. Cannabinoids (THC, nabilone) have shown efficacy in reducing nightmares, improving sleep, and dampening hyperarousal. Observational studies also note overall symptom improvement, though definitive RCT evidence is still limited. There is concern about dependency and heterogeneous responses. Nonetheless, PTSD is fast becoming one of the most accepted psychiatric indications for medical cannabis in jurisdictions where it is legal, with experts calling for larger trials to solidify guidance. For now, clinicians should consider cannabinoids in chronic PTSD on a case-by-case basis – for example, a veteran with debilitating insomnia and nightmares might benefit from a monitored nabilone or THC/CBD trial – while ensuring patients remain engaged in trauma-focused psychotherapy for core healing.

- Anxiety Disorders: CBD stands out as a promising anxiolytic. Multiple controlled studies have shown that CBD can reduce social anxiety acutely, and preliminary trials hint at efficacy in generalized anxiety with a remarkable safety/tolerability profile. On the other hand, high-THC cannabis is generally ill-advised for anxiety due to its potential to provoke panic or exacerbate anxiety at higher doses. Patients with milder anxiety may opt for over-the-counter CBD, but medical oversight is recommended for high-dose use. As evidence accumulates, we may see CBD integrated as an adjunct for anxiety disorders, particularly for those who do not fully respond to standard treatments or who seek a non-intoxicating alternative. It will be critical to standardize CBD formulations and dosing in practice (for instance, using pharmaceutical-grade CBD at ~300 mg/day as studied) to replicate the benefits seen in trials.

- Major Depressive Disorder: There is no reliable evidence that cannabis or cannabinoids improve depression; in fact, heavy THC use is linked to worsened depressive outcomes. While the endocannabinoid system is a novel target under investigation, at present cannabis cannot be recommended for MDD. Patients with depression should be cautioned that self-medicating with cannabis carries more risks (e.g. dependency, apathy) than proven benefits. Future research might explore whether isolated CBD or other cannabinoids have antidepressant effects, but until then, therapies like antidepressants, psychotherapy, and emerging modalities (e.g. ketamine, neuromodulation) remain the cornerstones of treatment.

- Insomnia: Cannabis-based medicines have demonstrated efficacy for insomnia, aligning with long-standing patient reports . Controlled data show improvements in sleep onset, duration, and quality with THC/CBD combinations, and patient satisfaction tends to be high. Medical cannabis could be considered as an alternative to conventional hypnotics for chronic insomnia, especially in those who also have chronic pain, PTSD, or anxiety (where it can address multiple issues). However, clinicians should monitor for tolerance and advise on proper timing/dosing to minimize next-day effects. As always, behavioural interventions for insomnia (CBT-I) should be concurrently encouraged, with cannabinoids as a pharmacological adjunct when needed.

- Eating Disorders: For anorexia nervosa, low-dose THC (dronabinol) has shown a modest but significant impact on weight gain in trials. This provides a proof of concept that targeting the endocannabinoid appetite pathways can aid in anorexia treatment. While not a standalone solution, dronabinol or similar could be considered in chronic or severe AN to augment weight restoration efforts, provided it is done under careful medical supervision (e.g. in an inpatient or day-program setting where intake is monitored). There is presently insufficient data to support use in bulimia or binge eating disorder, and it may be contraindicated in those cases due to THC's appetite-stimulating effect potentially exacerbating binges.

- Personality Disorders: The application of medical cannabis here is very preliminary. Early case evidence suggests potential symptom mitigation in borderline personality disorder with combined THC/CBD use, but this is far from an established therapy. If pursued, it should be within research or highly supervised contexts. Given the high morbidity of BPD and lack of approved medications, it is an area worthy of further study. Any interim use must weigh the individual's risk of substance misuse and ensure it complements ongoing psychotherapy.

In all cases, the potential benefits of medical cannabis must be weighed against its risks and the limitations of current knowledge. Side effects like cognitive dulling, dependence, and psychiatric adverse reactions (e.g. THC-induced anxiety or psychosis) are real considerations, particularly in developing youth or those with predispositions. Thus, a careful patient selection and "start low, go slow" dosing strategy is imperative when initiating cannabinoid therapy.

From a regulatory and ethical standpoint, continued rescheduling and destigmatization of cannabis will help facilitate large-scale research, which in turn can inform guidelines and training for clinicians. Patients deserve evidence-based guidance; many are already experimenting with cannabis products, and it is incumbent on the medical community to catch up with robust data and clear recommendations. Ethically, providers should neither reflexively dismiss medical cannabis (thus driving patients to black-market use without guidance) nor embrace it uncritically. Instead, an objective, compassionate approach is

needed – acknowledging patient reports, explaining known science, and co-creating a treatment plan that may include cannabinoids as one component when appropriate.

Final Thoughts

Medical cannabis sits at the intersection of hopeful promise and prudent caution in psychiatry. For some conditions (like PTSD nightmares or Tourette's tics), it offers a tangible new tool in our arsenal, potentially improving quality of life where standard treatments fall short. For others (like depression or primary OCD), the jury is still out, leaning towards no clear benefit with current evidence. Across the board, more high-quality research is needed to move from anecdote to solid guideline recommendations. In the meantime, clinicians and patients should engage in informed, open dialogue about medical cannabis, weighing the existing evidence and uncertainties. With careful use, ongoing monitoring, and a focus on individual response, cannabinoids could be harnessed to fill therapeutic gaps in modern psychiatry – but always in a way that prioritizes patient safety and complements established, effective treatments. The evolving legal landscape and accumulating scientific data make it likely that in the coming years we will better define the place of medical cannabis in the treatment of ADHD, ASD, Tourette's, OCD, PTSD, anxiety, depression, insomnia, eating disorders, and personality disorders – transforming tentative hope into well-founded clinical practice.

Sources: This review is informed by findings from recent systematic reviews, clinical trials, and meta-analyses in peer-reviewed journals, including evidence that CBD shows anxiolytic promise with minimal side effects, that THC/CBD preparations improved refractory tics in Tourette's, and that nabilone significantly reduced nightmares in PTSD patients, among others as cited throughout. These sources provide a foundation of evidence to guide the cautious integration of cannabinoid-based therapies into psychiatric practice where appropriate.

References

Abi-Jaoude, E., Chen, L., Cheung, P., Bhikram, T., & Sandor, P. (2017). Preliminary evidence on cannabis effectiveness and tolerability for adults with Tourette syndrome. Journal of Neuropsychiatry and Clinical Neurosciences, 29(4), 391–400. DOI: 10.1176/appi.neuropsych.16110310. PMID: 28464701.

Andries, A., Frystyk, J., Flyvbjerg, A., & Støving, R. K. (2014). Dronabinol in severe, enduring anorexia nervosa: a randomized controlled trial. International Journal of Eating Disorders, 47(1), 18–23. DOI: 10.1002/eat.22173. PMID: 24105610.

Anis, S., Zalomek, C., Korczyn, A. D., Rosenberg, A., Giladi, N., & Gurevich, T. (2022). Medical cannabis for Gilles de la Tourette syndrome: An open-label prospective study. Behavioural Neurology, 2022, Article 5141773, 1–10. DOI: 10.1155/2022/5141773. PMID: 35310886.

Aran, A., Cassuto, H., Lubotzky, A., Wattad, N., & Hazan, E. (2019). Brief report: Cannabidiol-rich cannabis in children with autism spectrum disorder and severe behavioural problems – a retrospective feasibility study. Journal of Autism and Developmental Disorders, 49(3), 1284–1288. DOI: 10.1007/s10803-018-3808-2. PMID: 30426533.

Aran, A., Harel, M., Cassuto, H., Polyansky, L., Schnapp, A., Wattad, N., Shmueli, D., Golan, D., & Castellanos, F. X. (2021). Cannabinoid treatment for autism: A proof-of-concept randomized trial. Molecular Autism, 12(1), Article 6, 1–11. DOI: 10.1186/s13229-021-00420-2. PMID: 33536055.

Barchel, D., Stolar, O., De-Haan, T., Ziv-Baran, T., Saban, N., Fuchs, D. O., Koren, G., & Berkovitch, M. (2019). Oral cannabidiol use in children with autism spectrum disorder to treat related symptoms and co-morbidities. Frontiers in Pharmacology, 9, Article 1521, 1–7. DOI: 10.3389/fphar.2018.01521. PMID: 30687090.

Bar-Lev Schleider, L., Mechoulam, R., Saban, N., Meiri, G., & Novack, V. (2019). Real life experience of medical cannabis treatment in autism: Analysis of safety and efficacy. Scientific Reports, 9(1), 200. DOI: 10.1038/s41598-018-37570-y. PMID: 30643350.

Bergamaschi, M. M., Queiroz, R. H. C., Chagas, M. H. N., de Oliveira, D. C. G., De Martinis, B. S., Kapczinski, F., Quevedo, J., Roesler, R., Schröder, N., Nardi, A. E., Martín-Santos, R., Hallak, J. E. C., Zuardi, A. W., & Crippa, J. A. S. (2011). Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology, 36(6), 1219–1226. DOI: 10.1038/npp.2011.6. PMID: 21307846.

Bonn-Miller, M. O., Sisley, S., Riggs, P., Yazar-Klosinski, B., Wang, J. B., Loflin, M. J. E., Shechet, B., Hennigan, C., Matthews, R., Emerson, A., & Doblin, R. (2021). The short-term impact of three smoked cannabis preparations versus placebo on PTSD symptoms: A randomized cross-over clinical trial. PLOS ONE, 16(3), e0246990, 1–18. DOI: 10.1371/journal.pone.0246990. PMID: 33730032.

Cooper, R. E., Williams, E., Seegobin, S., Tye, C., Kuntsi, J., & Asherson, P. (2017). Cannabinoids in attention-deficit/hyperactivity disorder: A randomized-controlled trial. European Neuropsychopharmacology, 27(8), 795–808. DOI: 10.1016/j.euroneuro.2017.05.005. PMID: 28576350.

Dhamija, D., Bello, A. O., Khan, A. A., Gutlapalli, S. D., Sohail, M., Patel, P. A., Midha, S., Shukla, S., & Mohammed, L. (2023). Evaluation of efficacy of cannabis use in patients with attention deficit hyperactivity disorder: A systematic review. Cureus, 15(6), e40969, 1–12. DOI: 10.7759/cureus.40969. PMID: 37503496.

Fleury-Teixeira, P., Caixeta, F. V., da Silva, L. C. R., Brasil-Neto, J. P., & Malcher-Lopes, R. (2019). Effects of CBD-enriched Cannabis sativa extract on autism spectrum disorder symptoms: An observational study of 18 participants undergoing compassionate use. Frontiers in Neurology, 10, 1145, 1–10. DOI: 10.3389/fneur.2019.01145. PMID: 31780966.

Hacohen, M., Stolar, O. E., Berkovitch, M., Elkana, O., Kohn, E., Hazan, A., Heyman, E., Sobol, Y., Waissengreen, D., Gal, E., & Dinstein, I. (2022). Children and adolescents with ASD treated with CBD-rich cannabis exhibit significant improvements particularly in social symptoms: An open label study. Translational Psychiatry, 12(1), Article 375, 1–11. DOI: 10.1038/s41398-022-02104-8. PMID: 36046013.

Hazani, R., Shoval, G., & Weller, A. (2021). Targeting the endocannabinoid system in borderline personality disorder: Corticolimbic and hypothalamic perspectives. Current Neuropharmacology, 19(3), 360–371. DOI: 10.2174/1570159X18666200429234430. PMID: 32351183.

Hernandez, M., & Levin, F. R. (2022). Attention-deficit hyperactivity disorder and therapeutic cannabis use motives. Psychiatric Clinics of North America, 45(3), 503–514. DOI: 10.1016/j.psc.2022.05.010. PMID: 36055735.

Jetly, R., Heber, A., Fraser, G., & Boisvert, D. (2015). The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology, 51, 585–588. DOI: 10.1016/j.psyneuen.2014.11.002. PMID: 25467221.

Kayser, R. R., Haney, M., Raskin, M., Arout, C. A., & Simpson, H. B. (2020). Acute effects of cannabinoids on symptoms of obsessive–compulsive disorder: A human laboratory study. Depression and Anxiety, 37(8), 801–811. DOI: 10.1002/da.23032. PMID: 32383271.

Lev-Ran, S., Roerecke, M., Le Foll, B., George, T. P., McKenzie, K., & Rehm, J. (2014). The association between cannabis use and depression: A systematic review and meta-analysis of longitudinal studies. Psychological Medicine, 44(4), 797–810. DOI: 10.1017/S0033291713001438. PMID: 23795762.

Masataka, N. (2019). Anxiolytic effects of repeated cannabidiol treatment in teenagers with social anxiety disorders. Frontiers in Psychology, 10, 2466, 1–10. DOI: 10.3389/fpsyg.2019.02466. PMID: 31824388.

Müller-Vahl, K. R., Schneider, U., Prevedel, H., Theloe, K., Kolbe, H., Daldrup, T., & Emrich, H. M. (2003). Delta⁹-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: A 6-week randomized trial. Journal of Clinical Psychiatry, 64(4), 459–465. DOI: 10.4088/JCP.v64n0417. PMID: 12716250.

Ponton, J. A., Smyth, K., Soumbasis, E., Llanos, S. A., Lewis, M., Meerholz, W. A., & Tanguay, R. L. (2020). A paediatric patient with autism spectrum disorder and epilepsy using cannabinoid extracts as complementary therapy: A case report. Journal of Medical Case Reports, 14(1), 162. DOI: 10.1186/s13256-020-02478-7. PMID: 32958062.

Shannon, S., Lewis, N., Lee, H., & Hughes, S. (2019). Cannabidiol in anxiety and sleep: A large case series. The Permanente Journal, 23, 18-041, 1–5. DOI: 10.7812/TPP/18-041. PMID: 30624194.

Szejko, N., Fremer, C., & Müller-Vahl, K. R. (2020). Cannabis improves obsessive–compulsive disorder – Case report and review of the literature. Frontiers in Psychiatry, 11, 681, 1–6. DOI: 10.3389/fpsyt.2020.00681. PMID: 32848902.

Walsh, J. H., Maddison, K. J., Rankin, T., Murray, K., McArdle, N., Ree, M. J., Hillman, D. R., & Eastwood, P. R. (2021). Treating insomnia symptoms with medicinal cannabis: A randomized, crossover trial of the efficacy of a cannabinoid medicine compared with placebo. Sleep, 44(11), zsab149, 1–13. DOI: 10.1093/sleep/zsab149. PMID: 34115851.